Carl Zeiss Meditec AG (CZMWY) Stock Price & Analysis
Carl Zeiss Meditec AG (CZMWY) — price $35.42 (+0.34%), as of the Nov 19, 2026 trading session; market cap $3.10B.
Educational signal · not a buy or sell recommendation · How to read this
Carl Zeiss Meditec AG · CZMWY
Carl Zeiss Meditec AG is a German medical technology company specializing in ophthalmic devices and microsurgery solutions. It provides diagnostic and treatment systems for eye diseases, alongside visualization solutions for various invasive surgical procedures globally.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $35.42 | |
| Change on the day | +0.34% | |
| 52-week range | $26.65 – $53.40 | |
| Market capitalisation | $3.10B | — |
| Price / earnings (trailing) | 20.60 | |
| Shares traded on the day | 200 |
Price & events
Other perspectives
Council score for Carl Zeiss Meditec AG (CZMWY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Carl Zeiss Meditec AG (CZMWY), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Carl Zeiss Meditec AG (CZMWY) is the company analyzed here. It employs 5,784 people and is led by Andreas Pecher. In Q3 FY2026 it reported revenue of €563M and net income of €55M. The market values it at $3.10B.
What do the latest results show for Carl Zeiss Meditec AG (CZMWY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of €563M. Against analyst estimates the company has EPS beat 0 of the last 6 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | €563M | €55M | €0.64 (diluted) |
| Q2 FY2026 | €1.00B | €15M | €0.17 (diluted) |
| Q1 FY2026 | €467M | -€5M | -€0.06 (diluted) |
| Q4 FY2025 | €628M | €52M | €0.90 (diluted) |
What are the financial strengths and risks for Carl Zeiss Meditec AG (CZMWY)?
Short answer · as of
The distress and quality screens read Piotroski F 7. Trailing ratios: ROE 5.5% · earnings yield 3.9% · free-cash-flow yield 8.9%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CZMWY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CZMWY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Carl Zeiss Meditec AG (CZMWY)?
- ZEISS to expand myopia solutions in China with NMPA's approval of ZEISS PT LUNANA phakic intraocular lens
- Carl Zeiss Meditec: Why The Market Is Finally Recognizing The Recovery
- Bronwyn Brophy O'Connor to Become CEO of Carl Zeiss Meditec Group in December 2026
- ZEISS announces availability of CT LUCIA 621P in Japan, expanding its broad ZEISS Cataract Workflow
Investor Questions: CZMWY Stock
These answers are editorial: 1 of these 8 answers is drawn from the CZMWY research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CZMWY a good stock to buy?
Stock Expert AI does not rate CZMWY buy, sell or hold. Carl Zeiss Meditec AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CZMWY stock price today?
The last price recorded for Carl Zeiss Meditec AG (CZMWY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are Carl Zeiss Meditec AG's core business segments and their offerings?
Carl Zeiss Meditec AG operates through two primary business segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment focuses on comprehensive solutions for eye care, providing advanced products for the diagnosis and treatment of various eye diseases.
What are the key factors to evaluate for CZMWY?
Evaluate CZMWY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. The company's continuous innovation in this area can lead to market share gains and revenue growth over the next decade. Not financial advice.
How frequently does CZMWY data refresh on this page?
CZMWY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CZMWY's recent stock price performance?
Carl Zeiss Meditec AG (CZMWY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand reputation and heritage from Carl Zeiss AG in precision optics and medical technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CZMWY overvalued or undervalued right now?
The trailing P/E of Carl Zeiss Meditec AG (CZMWY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CZMWY before investing?
Before investing in Carl Zeiss Meditec AG (CZMWY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com